ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Jan 27, 2025--
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ('Atara' or 'the Company') (NASDAQ: ATRA) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Atara announced on January 16, 2025, that it had received 'a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLO TM (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen.' According to the Company, 'The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO.'
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Brian Schall, Esq.
310-301-3335
SOURCE: The Schall Law Firm
Copyright Business Wire 2025.
PUB: 01/27/2025 10:43 AM/DISC: 01/27/2025 10:43 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
44 minutes ago
- Business Insider
‘Keep an Eye on the Bigger Picture,' Says Morgan Stanley About Tesla Stock
Tesla (NASDAQ:TSLA) stock took a sharp hit last week after Elon Musk and Donald Trump – once close buddies – turned on each other in a public social media spat that quickly became an online spectacle. While the internet grabbed its popcorn to watch the drama/comedy unfold, investors were less amused, driving the stock down and wiping out a record $152 billion in market value. Confident Investing Starts Here: Trump warned he might yank Elon's federal subsidies and contracts, while Musk took jabs at Trump's links to Jeffrey Epstein and called for his impeachment. Now, Trump says he's considering ditching his Tesla. But what does Wall Street have to say about all this madness? Morgan Stanley analyst Adam Jonas, one of the Street's biggest TSLA bulls, shared a 'few 'pith and marrow' thoughts' in the wake of the public spat. According to Trump, the whole thing kicked off because Musk was upset his 'Big Beautiful Bill' was not beneficial to Tesla. However, Jonas makes short shrift of the implications. 'We do not believe the phasing out of EV tax credits from the BBB (Big Beautiful Bill) is material to the long term outlook for TSLA,' the analyst said While Musk's involvement with the Trump administration and his increasingly polarizing politics were the cue from a massive drop in sales for Tesla earlier this year, Jonas does not think the argument will help bring back buyers that once considered buying a Tesla but were turned off by Musk's recent activities. In fact, Jonas thinks the argument could 'potentially (temporarily) alienate multiple sides of the political spectrum.' Yet, zooming out, Jonas thinks it's important to keep an eye on the bigger picture and that offers plenty of promise. 'While emotions are running high, we are not convinced the longer-term vectors that drive the stock's value have changed here,' he said. ' AI leadership, autonomy/robotics, manufacturing, supply chain re-architecture, renewable power, critical infrastructure… Tesla still holds so many valuable cards that are largely apolitical, in our opinion.' Nevertheless, investors should prepare for a rocky ride over the near-term. Donning his 'trading cap,' Jonas feels more confident about short-term volatility than about the stock's immediate direction. The analyst says he's sticking with his $410 price target on Tesla shares, even as he braces for the stock to post further losses. That figure implies a one-year gain of 36%. Meanwhile, Jonas maintains an Overweight rating (i.e., Buy). (To watch Jonas' track record, click here) That view, however, stands in contrast to the broader Street sentiment. Based on a mix of 16 Buys, 10 Holds, and 10 Sells, the analyst consensus rates the stock a Hold (i.e., Neutral). Going by the $285.91 average target, the shares are expected stay range-bound for the foreseeable future. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
an hour ago
- Yahoo
WPP CEO Mark Read to Retire at Year-End
Read—who has been at the company for more than 30 years—will retire from the board and as CEO on Dec. 31.
Business Insider
an hour ago
- Business Insider
Lululemon Athletica (LULU) Gets a Hold from Barclays
Barclays analyst Adrienne Yih maintained a Hold rating on Lululemon Athletica (LULU – Research Report) on June 6 and set a price target of $270.00. The company's shares closed last Friday at $265.27. Confident Investing Starts Here: Yih covers the Consumer Cyclical sector, focusing on stocks such as American Eagle, Dick's Sporting Goods, and VF. According to TipRanks, Yih has an average return of 6.4% and a 49.70% success rate on recommended stocks. In addition to Barclays, Lululemon Athletica also received a Hold from Morgan Stanley's Alexandra Straton in a report issued yesterday. However, on June 6, KeyBanc reiterated a Buy rating on Lululemon Athletica (NASDAQ: LULU). Based on Lululemon Athletica's latest earnings release for the quarter ending February 2, the company reported a quarterly revenue of $3.61 billion and a net profit of $748.4 million. In comparison, last year the company earned a revenue of $3.21 billion and had a net profit of $669.47 million
